Cost-effectiveness analysis of a low-cost bubble CPAP device in providing ventilatory support for neonates in Malawi - a preliminary report

BMC Pediatrics

Volumn 14, Issue 1, 2014, Pages

  Chen, Ariel ^a   Deshmukh, Ashish A ^b   Richards Kortum, Rebecca ^a,c   Molyneux, Elizabeth ^d   Kawaza, Kondwani ^d   Cantor, Scott B ^b  

^a RICE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Rice University   (United States)

^d UNIVERSITY OF MALAWI   (Malawi)

Author keywords

Bubble continuous positive airway pressure; Cost effectiveness analysis; Malawi; Neonate; Prematurity; Respiratory distress syndrome; Sepsis; Ventilatory support

Indexed keywords

OXYGEN;

ARTICLE; BIRTH WEIGHT; CASE STUDY; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HOSPITAL COST; HOSPITAL INFORMATION SYSTEM; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALAWI; NEONATAL VENTILATOR; NEWBORN; NEWBORN CARE; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; POSITIVE END EXPIRATORY PRESSURE VENTILATOR; PROBABILITY; QUALITY OF LIFE; RESPIRATORY DISTRESS SYNDROME; SEPSIS; SHELF LIFE; WORLD HEALTH ORGANIZATION; COMPLICATION; CONTROLLED CLINICAL TRIAL; DEVICES; ECONOMICS; INFANT; MORTALITY; OXYGEN THERAPY; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

CONTINUOUS POSITIVE AIRWAY PRESSURE; COST-BENEFIT ANALYSIS; HUMANS; INFANT; MALAWI; OXYGEN INHALATION THERAPY; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SEPSIS;

EID: 84964314043     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/s12887-014-0288-1     Document Type: Article

References (24)

1. Oestergaard MZ, Inoue M, Yoshida S, Mahanani WR, Gore FM, Cousens S, Lawn JE, Mathers CD, United Nations Inter-Agency Group for Child Mortality E, the Child Health Epidemiology Reference G: Neonatal mortality levels for 193 countries in 2009 with trends since 1990: a systematic analysis of progress, projections, and priorities. PLoS Med 2011, 8(8):e1001080.
2. Lawn JE, Kerber K, Enweronu-Laryea C, Cousens S: 3.6 million neonatal deaths-what is progressing and what is not? Semin Perinatol 2010, 34(6):371-386.
3. Kamath BD, Macguire ER, McClure EM, Goldenberg RL, Jobe AH: Neonatal mortality from respiratory distress syndrome: lessons for low-resource countries. Pediatrics 2011, 127(6):1139-1146.
4. March of Dimes, PMNCH, Save the Children, WHO: Born Too Soon: The Global Action Report on Preterm Birth. In Edited by Howson CP, Kinney MV, Lawn JE. Geneva: World Health Organization; 2012.
5. You D, New RJ, Wardlaw T: Levels and Trends in Child Mortality: Estimates Developed by the UN Inter-Agency Group for Child Mortality Estimation. New York: UNICEF; 2012.
6. Brown J, Machen H, Kawaza K, Mwanza Z, Iniguez S, Lang H, Gest A, Kennedy N, Miros R, Richards-Kortum R, Molyneux E, Oden M: A high-value, low-cost bubble continuous positive airway pressure system for low-resource settings: technical assessment and initial case reports. PLoS ONE 2013, 8(1):e53622.
7. Koyamaibole L, Kado J, Qovu JD, Colquhoun S, Duke T: An evaluation of bubble-CPAP in a neonatal unit in a developing country: effective respiratory support that can be applied by nurses. J Trop Pediatr 2006, 52(4):249-253.
8. Kawaza K, Machen HE, Brown J, Mwanza Z, Iniguez S, Gest A, Smith EO, Oden M, Richards-Kortum RR, Molyneux E: Efficacy of a low-cost bubble CPAP system in treatment of respiratory distress in a Neonatal Ward in Malawi. PLoS ONE 2014, 9(1):e86327.
9. Hoch JS, Briggs AH, Willan AR: Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002, 11(5):415-430.
10. Briggs AH, O'Brien BJ, Blackhouse G: Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002, 23:377-401.
11. World Health Organization: Global Health Observatory Data Repository, Mortality and global health estimates, Life expectancy: Life tables for Malawi. Geneva: World Health Organization; 2011. http://apps.who.int/gho/data/ view.main.60980 (accessed on April 14, 2014).
12. Baltussen R, Adam T, Edejer TTT, Hutubessy R, Acharya A, Evans DB, Murray CJL: Part One: Methods for Generalized Cost-Effectiveness Analysis. In Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Edited by Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. Geneva: World Health Organization; 2003.
13. Adam T, Evans DB, Murray CJ: Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003, 1(1):3.
14. U.S. Bureau of Labor Statistics: Consumer Price Index for All Urban Consumers: Medical Care Services. Washington, DC: U.S. Bureau of Labor Statistics; 2014. http://data.bls.gov/cgi-bin/surveymost?cu (accessed on April 14, 2014).
15. Hoch JS: Improving efficiency and value in palliative care with net benefit regression: an introduction to a simple method for cost-effectiveness analysis with person-level data. J Pain Symptom Manage 2009, 38(1):54-61.
16. Hoch JS, Rockx MA, Krahn AD: Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Serv Res 2006, 6:68.
17. Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, Lamy A, Culler S, Caro J, Yusuf S, Weintraub WS, Cure Study Investigators: Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006, 151(1):219-227.
18. van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994, 3(5):309-319.
19. Hutubessy R, Chisholm D, Edejer T, WHO-CHOICE: Generalized costeffectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation 2003, 1(1):8.
20. The World Bank: GDP per capita (current US$). Washington, DC: The World Bank Group; 2013. http://data.worldbank.org/country/malawi (accessed on April 14, 2014).
21. Vento M: Oxygen supplementation in the neonatal period: changing the paradigm. Neonatology 2014, 105(4):323-331.
22. Gilbert C: Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008, 84(2):77-82.
23. Zepeda-Romero LC, Barrera-de-Leon JC, Camacho-Choza C, Gonzalez Bernal C, Camarena-Garcia E, Diaz-Alatorre C, Gutierrez-Padilla JA, Gilbert C: Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city. Mexico. Br J Ophthalmol 2011, 95(11):1502-1505.
24. Enarson P, La Vincente S, Gie R, Maganga E, Chokani C: Implementation of an oxygen concentrator system in district hospital paediatric wards throughout Malawi. Bull World Health Organ 2008, 86(5):344-348.